Arbutus Biopharma

ABUS

Market cap $815M

65 hedge funds and large institutions have $75.5M invested in Arbutus Biopharma in 2020 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 9 increasing their positions, 16 reducing their positions, and 16 closing their positions.

New

Increased

Maintained

Reduced

Closed

2025 Q2 2025 Q1 2024 Q4 2024 Q3 2024 Q2 2024 Q1 2023 Q4 2023 Q3 2023 Q2 2023 Q1 2022 Q4 2022 Q3 2022 Q2 2022 Q1 2021 Q4 2021 Q3 2021 Q2 2021 Q1 2020 Q4 2020 Q3 2020 Q2 2020 Q1 2019 Q4 2019 Q3 2019 Q2 2019 Q1 2018 Q4 2018 Q3 2018 Q2 2018 Q1 2017 Q4 2017 Q3 2017 Q2 2017 Q1 2016 Q4 2016 Q3 2016 Q2 2016 Q1 2015 Q4 2015 Q3 2015 Q2 2015 Q1 2014 Q4 2014 Q3 2014 Q2 2014 Q1 2013 Q4 2013 Q3 2013 Q2

Holders

Holders Change

+14

Holders Change %

+27.45%

% of All Funds

1.31%

Holding in Top 10

–

Holding in Top 10 Change

-1

Holding in Top 10 Change %

-100%

% of All Funds

–

New

Increased

Reduced

Closed

Calls

$1.5M

Puts

$1.87M

Net Calls

-$373K

Net Calls Change

-$1.58M

Top Buyers

1	FCMI 1 Foresite Capital Management IV Larkspur, California	$10.4M
2	TI 2 Think Investments San Francisco, California	$6.26M
3	3 BlackRock New York	$3.27M
4	4 Ameriprise Minneapolis, Minnesota	$2.05M
5	5 Vanguard Group Malvern, Pennsylvania	$7.02M

Top Sellers

1	CAC 1 Cowen and Company New York	$1.48M
2	2 Goldman Sachs New York	$795K
3	3 Citadel Advisors Miami, Florida	$219K
4	RI 4 RTW Investments New York	$18.7M
5	5 Morgan Stanley New York	$9.11M